SCHEMBL5768033

SCHEMBL5768033

CCOC(=O)C(=CN(OC)c1ccccc1)C(=O)OCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
MAPT P10636 6/20 0.48
LMNA P02545 3/20 0.48
GAA P10253 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
PLIN1 O60240 1/20 0.48
POLB P06746 1/20 0.48
PLIN5 Q00G26 1/20 0.48
ABHD5 Q8WTS1 1/20 0.48
DHODH Q02127 3/20 0.44
NR1H4 Q96RI1 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 3/20 0.42
NPSR1 Q6W5P4 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
S1PR4 O95977 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5094475 0.83 MEN1 (0.60) MEN1KMT2AMAPTLMNAGAA
SCHEMBL5089790 0.81 MEN1 (0.58) MEN1KMT2AMAPTLMNAGAA
SCHEMBL5765975 0.80 NPSR1 (0.38) MEN1KMT2ATDP1TSHRALDH1A1
SCHEMBL398239 0.78 MEN1 (0.54) MEN1KMT2AMAPTLMNAGAA
SCHEMBL11281728 0.77 MEN1 (0.50) MEN1KMT2AMAPTLMNAGAA
SCHEMBL9094971 0.75 MEN1 (0.54) MEN1KMT2AMAPTLMNAGAA
SCHEMBL9094974 0.75 MEN1 (0.54) MEN1KMT2AMAPTLMNAGAA
SCHEMBL11272186 0.74 MEN1 (0.50) MEN1KMT2AMAPTLMNAGAA
SCHEMBL10861409 0.73 KMT2A (0.55) MEN1KMT2AMAPTLMNAGAA
SCHEMBL10868370 0.72 MEN1 (0.48) MEN1KMT2AMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148232-B2 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-12-12 US disclosed
EP-1380587-B1 Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2006-03-15 EP disclosed
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2005-02-03 US disclosed
US-6809203-B2 IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA 3M INNOVATIVE PROPERTIES COMPANY 2004-10-26 US disclosed
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6703402-B2 IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-03-09 US disclosed
EP-1380587-A2 Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof 3M Innovative Properties Company (US) 2004-01-14 EP disclosed
US-6677334-B2 IMMUNOMODULATORS, INDUCE CYTOKINE BIOSYNTHESIS, AND ANTINEOPLASTIC AGENTS 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-10-16 US disclosed
US-6627640-B2 Viricides; anticancer agents 3M INNOVATIVE PROPERTIES COMPANY 2003-09-30 US disclosed
EP-1100802-B1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2003-09-24 EP disclosed
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-03-06 US disclosed
US-6440992-B1 ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-27 US disclosed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US disclosed
US-6323200-B1 THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. 3M INNOVATIVE PROPERTIES COMPANY 2001-11-27 US disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, IL2, IRF3 MEN1 2840/4885KMT2A 2907/4885MAPT 3413/4885
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MEN1 3773/4885KMT2A 2482/4885MAPT 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.